Triptorelin: Side Effects

Safety Profile Overview#

Triptorelin has a well-characterized safety profile based on decades of clinical use and extensive post-marketing surveillance. As an FDA-approved pharmaceutical, its adverse effects are documented in prescribing information derived from randomized controlled trials involving thousands of patients. The majority of side effects are predictable consequences of the intended hormonal suppression rather than off-target toxicities, making them largely unavoidable during therapy.

The side effect profile is dominated by symptoms of hypogonadism: the same hormonal suppression that provides therapeutic benefit also causes the most common adverse effects. Understanding this relationship is essential for patient counseling and expectation management.

Hormone-Related Side Effects#

Vasomotor Symptoms (Hot Flashes)#

Hot flashes are the most prevalent side effect, reported in 50-75% of patients across all indications. They result from the acute withdrawal of sex steroid feedback on the hypothalamic thermoregulatory center. The severity and frequency of hot flashes are often greatest during the initial months of therapy and may partially diminish over time as the body adapts to the hypogonadal state.

Management strategies include environmental measures (cool ambient temperature, layered clothing, fans), behavioral approaches (stress reduction, avoidance of triggers such as hot beverages, spicy food, and alcohol), pharmacological options in severe cases (low-dose venlafaxine, gabapentin, or megestrol acetate), and add-back hormone therapy in endometriosis patients.

Sexual Dysfunction#

In men treated for prostate cancer, sexual dysfunction is nearly universal during triptorelin therapy. Effects include loss of libido (60-95% of patients), erectile dysfunction (50-85%), decreased testicular volume, and gynecomastia (5-10%). These effects are directly attributable to castrate testosterone levels and are generally reversible upon treatment discontinuation, though recovery may be incomplete in some patients, particularly after prolonged therapy.

In women treated for endometriosis, decreased libido, vaginal dryness, and dyspareunia result from the hypoestrogemic state. Add-back therapy with low-dose norethisterone or tibolone can mitigate these symptoms without compromising therapeutic efficacy.

Bone Mineral Density Loss#

Progressive bone mineral density (BMD) loss is one of the most significant long-term consequences of triptorelin therapy. Both testosterone and estrogen are essential for maintaining bone homeostasis, and their suppression accelerates bone resorption.

• Rate of loss: Approximately 2-5% BMD loss per year during GnRH agonist therapy
• Reversibility: Partially reversible after treatment discontinuation, though complete recovery may not occur after prolonged therapy
• Fracture risk: Long-term ADT for prostate cancer is associated with a significantly increased fracture risk
• Monitoring: Baseline and periodic DEXA scans are recommended for patients on prolonged therapy
• Prevention: Calcium (1000-1200 mg daily) and vitamin D (800-1000 IU daily) supplementation; bisphosphonates or denosumab in high-risk patients

Metabolic Effects#

Androgen deprivation therapy with triptorelin is associated with metabolic syndrome components including weight gain (particularly central adiposity), insulin resistance and increased risk of type 2 diabetes, dyslipidemia (increased LDL and triglycerides), and decreased lean body mass and increased fat mass. These metabolic changes emerge gradually during treatment and contribute to the cardiovascular risk associated with long-term ADT.

Cardiovascular Risk#

Epidemiological data suggest an association between GnRH agonist use and increased cardiovascular events, particularly in men with pre-existing cardiovascular disease. The mechanisms may include metabolic syndrome effects, changes in arterial stiffness and endothelial function, and QT interval prolongation. The HERO trial demonstrated that the oral GnRH antagonist relugolix was associated with fewer major cardiovascular events than GnRH agonists, suggesting a class-specific risk rather than a general consequence of hormone deprivation.

Mood and Cognitive Effects#

Hypogonadism from triptorelin therapy can affect mood and cognition. Depression occurs in approximately 5-15% of patients and should be actively screened for. Cognitive changes including difficulty with concentration and memory have been reported. Emotional lability, irritability, and anxiety are common. These effects are generally reversible upon treatment discontinuation.

Testosterone Flare#

The initial stimulatory phase of triptorelin therapy produces a transient surge in testosterone (in men) or estradiol (in women) lasting 1-2 weeks. In prostate cancer patients, this flare can cause clinically significant complications.

Tumor flare symptoms include:

• Acute exacerbation of bone pain from skeletal metastases
• Ureteral or bladder outlet obstruction from tumor swelling
• Spinal cord compression from vertebral metastases (a medical emergency)
• Worsening of lower urinary tract symptoms

Flare prevention: The standard approach is to co-administer an anti-androgen (bicalutamide 50 mg daily or flutamide 250 mg three times daily) beginning 1 week before triptorelin initiation and continuing for 2-3 weeks after. Alternatively, a GnRH antagonist (degarelix or relugolix) can be used instead to avoid flare entirely.

Injection-Related Effects#

Depot triptorelin injections may cause local reactions including transient pain at the injection site (common), local erythema and induration (uncommon), sterile abscess (rare), and granuloma at the injection site (rare). Proper intramuscular injection technique is essential to ensure adequate drug delivery and minimize local complications.

Contraindications#

Pregnancy#

Triptorelin is classified as FDA Pregnancy Category X. GnRH agonists can cause fetal harm and may increase the risk of spontaneous abortion. Pregnancy must be excluded before initiating treatment, and effective non-hormonal contraception should be used during therapy in premenopausal women.

Hypersensitivity#

Patients with known hypersensitivity to triptorelin, native GnRH, or any component of the formulation should not receive the drug. Rare cases of anaphylaxis and serious allergic reactions have been reported with GnRH agonists.

Drug Interactions#

Anti-Androgens#

Anti-androgens are intentionally co-administered with triptorelin in prostate cancer to prevent testosterone flare and may be continued as combined androgen blockade. Monitor for additive side effects including hepatotoxicity (with flutamide) and gynecomastia.

QT-Prolonging Drugs#

Androgen deprivation therapy may prolong the QT interval. Caution is warranted when combining triptorelin with other QT-prolonging medications including certain antiarrhythmics, antibiotics (fluoroquinolones, macrolides), and psychiatric medications (antipsychotics, certain antidepressants). Baseline and periodic ECG monitoring may be appropriate in patients receiving multiple QT-prolonging agents.

Bone-Depleting Agents#

Concurrent use of corticosteroids, aromatase inhibitors, or other medications that reduce bone density may produce additive BMD loss when combined with triptorelin. Enhanced monitoring and preventive measures are warranted.

Long-Term Safety Considerations#

Long-term triptorelin therapy (beyond 6-12 months) raises additional safety considerations including progressive bone density loss with increasing fracture risk, cumulative cardiovascular risk from metabolic changes, potential for irreversible changes in body composition, and psychological impact of prolonged hypogonadism. For prostate cancer patients requiring indefinite ADT, intermittent therapy (cycles of treatment and treatment-free intervals) has been studied as a strategy to reduce cumulative side effects while maintaining disease control.

Related Reading#

• Triptorelin overview and research guide
• Triptorelin dosing protocols
• Triptorelin risks and legal status